Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference
January 04, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical Programs
December 19, 2016 07:00 ET
|
Actinium Pharmaceuticals
- Dr. Larrieux brings significant experience managing analytical development quality control of immunotherapies to treat cancer and small molecule therapies at pharmaceutical and biotechnology...
Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A
December 13, 2016 07:00 ET
|
Actinium Pharmaceuticals
- Actimab-A has received Orphan Drug Designation in the U.S. - Orphan Designation in the EU can result in regulatory assistance, reduced fees and 10 years of market exclusivity ...
Actinium to Sponsor Upcoming Blood & Marrow Transplant Information Network Webinar Focused on Stem Cell Transplants for Patients with AML
December 12, 2016 07:00 ET
|
Actinium Pharmaceuticals
Patient focused webinar titled “Stem Cell Transplants for Acute Myeloid Leukemia: What you Need to Know” Webinar to be led by transplant expert, Dr. Patrick Stiff, Director of the Cardinal...
Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting
December 05, 2016 21:00 ET
|
Actinium Pharmaceuticals
Analysis of 2 Actimab-A Phase 1 clinical trials show that 42% of patients with low peripheral blast (PB) burden responded to Actimab-A while no patients with high PB burden responded to Actimab-AKey...
Actinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical Trials
November 29, 2016 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Issues Letter to Shareholders Highlighting 2016 Accomplishments and Anticipated Milestones for 2017
November 22, 2016 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals to Present at LD Micro Main Event Investor Conference
November 21, 2016 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Announces Notice of Allowance for U.S. Patent Related to Actimab-A
November 14, 2016 07:00 ET
|
Actinium Pharmaceuticals
Allowed patent application claims method for purifying actinium-225 NEW YORK, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a...
INC Research Selected to Manage The Leukemia & Lymphoma Society’s First-ever Master Trial to Advance New Targeted Therapies for Acute Myeloid Leukemia
November 07, 2016 11:15 ET
|
INC Research, LLC
RALEIGH, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced its involvement in The...